Subarna Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.30 M
- Company Age 27 Year, 6 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 1.00 M
- Revenue Growth -51.56%
- Profit Growth 42.68%
- Ebitda 43.08%
- Net Worth -14.43%
- Total Assets 9.95%
About Subarna Pharmaceuticals
Subarna Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 August 1997 and has a history of 27 years and six months. Its registered office is in 24 Parganas, West Bengal, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M.
The company currently has active open charges totaling ₹1.00 M.
Jolly Dutta and Riya Datta serve as directors at the Company.
Company Details
- Location
24 Parganas, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231WB1997PTC085268
- Company No.
085268
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Aug 1997
- Date of AGM
15 Sep 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Subarna Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jolly Dutta  | Director | 27-Aug-1997 | Current |
| Riya Datta | Director | 20-May-2013 | Current |
Financial Performance of Subarna Pharmaceuticals.
Subarna Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 51.56% decrease. The company also saw a substantial improvement in profitability, with a 42.68% increase in profit. The company's net worth observed a substantial decline by a decrease of 14.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Subarna Pharmaceuticals?
In 2017, Subarna Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Jan 2000 | State Bank Of India | ₹1.00 M | Open |
How Many Employees Work at Subarna Pharmaceuticals?
Unlock and access historical data on people associated with Subarna Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Subarna Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Subarna Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
